Incretin-based therapies and their future in Type 2 diabetes mellitus

Therapy

Volumn 8, Issue 2, 2011, Pages 143-152

  Sonnett, Travis E ^a   Robinson, Jennifer D ^a   Bowen, Kurt A ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

diabetes mellitus; DPP 4; exenatide; GLP 1; incretin; liraglutide; saxagliptin; sitagliptin; vildagliptin

Indexed keywords

ACARBOSE; EXENDIN 4; GLIBENCLAMIDE; GLIMEPIRIDE; INCRETIN; INSULIN; INSULIN DETEMIR; INSULIN GLARGINE; LIRAGLUTIDE; METFORMIN; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; VILDAGLIPTIN;

ARTICLE; COMBINATION CHEMOTHERAPY; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG EFFICACY; HUMAN; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; SIDE EFFECT; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 79953238944     PISSN: 14750708     EISSN: 1744831X     Source Type: Journal    
DOI: 10.2217/thy.11.4     Document Type: Article

References (86)

1. Lee WWR: An overview of pediatric obesity. Pediatric Diabetes 8(Suppl. 9), 76-87 (2007).
2. Bloomgarden ZT: Adiposity and diabetes. Diabetes Care 25(12), 2342-2349 (2002).
3. Bays HE, Chapman RH, Grandy S; SHIELD Investigators' Group: The relationship of body mass index to diabetes mellitus, hypertension and dyslipidaemia: comparison of data from two national surveys. Int. J. Clin. Pract. 61(5), 737-747 (2007).
4. Flegal KM, Carroll MD, Ogden CL, Curtin LR: Prevalence and trends in obesity among US adults, 1999-2008. JAMA 303(3), 235-241 (2010).
5. Nguyen NT, Nguyen XM, Lane J, Wang P: Relationship between obesity and diabetes in a US adult population: findings from the National Health and Nutrition Examination Survey, 1999-2006. Obes. Surg. 21(3), 351-355 (2011).
6. Defronzo RA: Impaired glucose tolerance: do pharmacological therapies correct the underlying metabolic disturbance? Br. J. Diabetes Vasc. Dis. 3(Suppl. 1), S24-S40 (2003).
7. Monkhouse SJ, Morgan JD, Bates SE, Norton SA: An overview of the management of morbid obesity. Postgrad. Med. J. 85(1010), 678-681 (2009).
8. Inzucchi SE: Oral antihyperglycemic therapy for Type 2 diabetes: scientific review. JAMA 287(3), 360-372 (2002).
9. Baggioa LL, Drucker DJ: Biology of incretins: GLP-1 and GIP. Gastroenterology 132(6), 2131-2157 (2007).
10. Gallwitz B: The evolving place of incretinbased therapies in Type 2 diabetes. Pediatr. Nephrol. 25(7), 1207-1217 (2010).
11. Drucker DJ, Nauck MA: The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in Type 2 diabetes. Lancet 368(11), 1696-1705 (2006).
12. Defronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD: Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with Type 2 diabetes. Diabetes Care 28(5), 1092-1100 (2005).
13. Cryer PE: The barrier of hypoglycemia in diabetes. Diabetes 57, 3169-3176 (2008).
14. Gerich JE: Redefining the clinical management of Type 2 diabetes: matching therapy to pathophysiology. Eur. J. Clin. Invest. 32(3), 46-53 (2002).
15. Gilbert MP, Pratley RE: Efficacy and safety of incretin-based therapies in patients with Type 2 diabetes mellitus. Am. J. Med. 122(6 Suppl. 1), S11-S24 (2009).
16. Rodbard HW, Davidson JA, Garber AJ, Handelsman Y, Lebovitz H, Moghissi ES: Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology Consensus Panel on Type 2 diabetes mellitus: an algorithm for glycemic control. Endocr. Pract. 15(6), 540-559 (2009). Thorough explanation and outline of current treatment recommendations.
17. Rodbard HW, Davidson JA, Garber AJ, Handelsman Y, Lebovitz H, Moghissi ES: Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology Consensus Panel on Type 2 diabetes mellitus: an algorithm for glycemic control. Endocr. Pract. 15(7), 768-770 (2009). Thorough coverage and algorithm for current diabetes care.
18. Nathan DM, Buse JB, Davidson MB et al.: Medical management of hyperglycemia in Type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 32(1), 193-203 (2009). Current American Diabetes Association (ADA) standards of care and treatment guidelines for comparison to American Association of Clinical Endocrinologists/ American College of Endocrinology (AACE/ACE).
19. Byetta®, package insert. Amylin Pharmaceuticals, Inc; San Diego, CA, USA.
20. Drucker DJ, Buse JB, Taylor K et al.: Exenatide once weekly versus twice daily for the treatment of Type 2 diabetes: a randomized, open-label, non-inferiority study. Lancet 372(9645), 1240-1250 (2008).
21. Moretto TJ, Milton DR, Ridge TD et al.: Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with Type 2 diabetes: a randomized, double-blind, placebocontrolled, parallel group study. Clin. Ther. 30(8), 1448-1460 (2008).
22. Buse JB, Henry RR, Han J et al.: Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with Type 2 diabetes. Diabetes Care 27(11), 2628-2635 (2004).
23. Kendall DM, Riddle MC, Rosenstock J et al.: Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with Type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 28(5), 1083-1091 (2005).
24. Zinman B, Hoogwerf BJ, Duran Garcia S et al.: The effect of adding exenatide to a thiazoledinedione in suboptimally controlled Type 2 diabetes: a randomized trial. Ann. Intern. Med. 146(7), 477-485 (2007).
25. Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG: Exenatide versus insulin glargine in patients with suboptimally controlled Type 2 diabetes: a randomized trial. Ann. Intern. Med. 143(8), 559-569 (2005).
26. Barnett AH, Burger J, Johns D et al.: Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with Type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. Clin. Ther. 29(11), 2333-2348 (2007).
27. Nauck MA, Duran S, Kim D et al.: A comparison of twice-daily exenatide and biphasic insulin aspart in patients with Type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a noninferiority study. Diabetologia 50(2), 259-267 (2007).
28. Defronzo Ra, Triplitt C, Qu Y, Lewis MS, Maggs D, Glass LC: Effects of exenatide plus rosiglitazone on b cell function and insulin sensitivity in subjects with Type 2 diabetes on metformin. Diabetes Care 33(5), 951-957 (2010).
29. Victoza®, package insert. Novo Nordisk, Inc., Princeton, NJ, USA.
30. Buse JB, Rosenstock J, Sesti G et al.: Liraglutide once a day versus exenatide twice a day for Type 2 diabetes: a 26-week, randomized, parallel-group, multinational, open-label trial (LEAD-6). Lancet 374(9683), 39-47 (2009).
31. Garber A, Henry R, Ratner R et al.: Liraglutide versus glimepiride monotherapy for Type 2 diabetes (LEAD-3 Mono): randomized, 52-week, Phase III, double blind, parallel treatment trial. Lancet 373(9662), 473-481 (2009).
32. Marre M, Shaw J, Brandle M et al.: Liraglutide, a once-daily human GLP-1 analogue, added to a sulfonylurea over 26 weeks produces greater improvements in glycemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet. Med. 26(3), 268-278 (2009).
33. Nauck MA, Frid A, Hermansen K et al.: Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in Type 2 diabetes: the LEAD (Liraglutide Effect and Action in Diabetes)-2 study. Diabetes Care 32(1), 84-90 (2009).
34. Zinman B, Gerich J, Buse J et al.: Efficacy and safety of the human GLP-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with Type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 32(7), 1224-1230 (2009).
35. Russell-Jones D, Vaag A, Schmitz O et al.: Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in Type 2 diabetes mellitus (LEAD-5+met+su); a randomized controlled trial. Diabetologia 52(10), 2046-2055 (2009).
36. Pratley RE, Nauck M, Bailey T et al.: Liraglutide versus sitagliptin for patients with Type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomized, parallel-group, open-label trial. Lancet 375(9724), 1447-1456 (2010).
37. Januvia®, package insert. Merck and Co., Inc., Whitehouse Station, NJ, USA.
38. Aschner P, Kipnes MS, Lunceford JK et al.: Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with Type 2 diabetes. Diabetes Care 29(12), 2632-2637 (2006).
39. Raz I, Hanefeld M, Xu L et al.: Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with Type 2 diabetes mellitus. Diabetologia 49(11), 2564-2571 (2006).
40. Goldstein BJ, Feinglos MN, Lunceford JK et al.: Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with Type 2 diabetes. Diabetes Care 30(8), 1979-1987 (2007).
41. Rosenstock J, Brazg R, Andryuk PJ et al.: Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with Type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin. Ther. 28(10), 1556-1568 (2006).
42. Charbonnel B, Karasik A, Liu J et al.: Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with Type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 29(12), 2638-2643 (2006).
43. Hermansen K, Kipnes M, Luo E et al.: Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with Type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes. Metab. 9(5), 733-745 (2007).
44. Nauck MA, Meininger G, Sheng D et al.: Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with Type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes. Metab. 9(2), 194-205 (2007).
45. Raz I, Chen Y, Wu M et al.: Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with Type 2 diabetes. Curr. Med. Res. Opin. 24(2), 537-550 (2008).
46. Hollander P, Raslova K, Skjoth TV et al.: Efficacy and safety of insulin detemir once-daily in combination with sitagliptin and metformin: the TRANSITION randomised controlled trial. Diabetes Obes. Metab. 13(3), 268-275 (2011).
47. Onglyza®, package insert. Bristol-Meyers Squibb Co., Princeton, NJ, USA.
48. Rosenstock J, Sankoh S, List JF: Glucoselowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug naïve patients with Type 2 diabetes. Diabetes Obes. Metab. 10(5), 376-386 (2008).
49. Rosenstock J, Aguilar-Salinas C, Klein E et al.: Effect of saxagliptin monotherapy in treatment-naive patients with Type 2 diabetes. Curr. Med. Res. Opin. 25(10), 2401-2411 (2009).
50. Defronzo RA, Hissa MN, Garber AJ et al.: The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled Type 2 diabetes with metformin alone. Diabetes Care 32(9), 1649-1655 (2009).
51. Jadzinsky M, Pfutzner A, Paz-Pacheco E et al.: Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with Type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes. Metab. 11(6), 611-622 (2009).
52. Chacra AR, Tan GH, Apanovitch A et al.: Saxagliptan added to a submaximal dose of sulphonylurea improves glycemic control compared with uptitration of sulphonylurea in patients with Type 2 diabetes: a randomized controlled trial. Int. J. Clin. Pract. 63(9), 1395-1406 (2009).
53. Hollander P, Li J, Allen E et al.: Saxagliptin added to a thiazolidinedione improves glycemic control in patients with Type 2 diabetes and inadequate control on thiazolidinedione alone. J. Clin. Endocrinol. Metab. 94(12), 4810-4819 (2009).
54. Scherbaum WA, Schweizer A, Mari A et al.: Efficacy and tolerability of vildagliptin in drug-naïve patients with Type 2 diabetes and mild hyperglycemia. Diabetes Obes. Metab. 10(8), 675-682 (2008).
55. Scherbaum WA, Schweizer A, Mari A et al.: Evidence that vildagliptin attenuates deterioration of glycemic control during 2-year treatment of patients with Type 2 diabetes and mild hyperglycemia. Diabetes Obes. Metab. 10(11), 1114-1124 (2008).
56. Dejager S, Razac S, Foley JE, Schweizer A: Vildagliptin in drug-naïve patients with Type 2 diabetes: a 24-week, double blind, randomized, placebo-controlled, multiple-dose study. Horm. Metab. Res. 39(3), 218-223 (2007).
57. Schweizer A, Couturier A, Foley JE, Dejager S: Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naïve patients with Type 2 diabetes. Diabet. Med. 24(9), 955-961 (2007).
58. Rosenstock J, Baron MA, Dejager S, Mills D, Schweizer A: Comparison of vildagliptin and rosiglitazone monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Care 30(2), 217-223 (2007).
59. Rosenstock J, Kim SW, Baron MA et al.: Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with Type 2 diabetes. Diabetes Obes. Metab. 9(2), 175-185 (2007).
60. Pan C, Yang W, Barona JP et al.: Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial. Diabet. Med. 25(4), 435-441 (2008).
61. Garber AJ, Foley JE, Banerji MA et al.: Effects of vildagliptin on glucose control in patients with Type 2 diabetes inadequately controlled with a sulphonylurea. Diabetes Obes. Metab. 10(11), 1047-1056 (2008).
62. Bosi E, Camisasca RP, Collober C, Rochette E, Garber AJ: Effects of vildagliptin on glucose control over 24 weeks in patients with Type 2 diabetes inadequately controlled with metformin. Diabetes Care 30(4), 890-895 (2007).
63. Garber AJ, Schweizer A, Baron MA, Rochette E, Dejager S: Vildagliptin in combination with pioglitazone improves glycemic control in patients with Type 2 diabetes failing thiazoledinedione monotherapy: a randomized, placebo-controlled study. Diabetes Obes. Metab. 9(2), 166-174 (2007).
64. Fonseca V, Schweizer A, Albrecht D, Baron MA, Chang I, Dejager S: Addition of vildagliptin to insulin improves glycemic control in Type 2 diabetes. Diabetologia 50(6), 1148-1155 (2007).
65. Haslam DW, James WP: Obesity. Lancet 366(9492), 1197-1209 (2005).
66. Colditz GA, Willett WC, Rotnitzky A, Manson JE: Weight gain as a risk factor for clinical diabetes mellitus in women. Ann. Intern. Med. 122(7), 481-486 (1995).
67. Field AE, Coakley EH, Must A et al.: Impact of overweight on the risk of developing common chronic diseases during a 10-year period. Arch. Intern. Med. 161(13), 1581-1586 (2001).
68. Hart CL, Hole DJ, Lawlor DA, Vey Smith G: How many cases of Type 2 diabetes mellitus are due to being overweight in middle age? Evidence from the Midspan prospective cohort studies using mention of diabetes mellitus on hospital discharge or death records. Diabet. Med. 24(1), 73-80 (2007).
69. Narayan KM, Boyle JP, Thompson TJ, Gregg EW, Williamson DF: Effect of BMI on lifetime risk for diabetes in the US. Diabetes Care 30(6), 1562-1566 (2007).
70. Wannamethee SG, Shaper AG, Walker M: Overweight and obesity and weight change in middle aged men: impact on cardiovascular disease and diabetes. J. Epidemiol. Comm. Health 59(2), 134-139 (2005).
71. Flint A, Raben A, Astrup A, Holst JJ: Glucagon-like peptide-1 promotes satiety and suppresses energy intake in humans. J. Clin. Invest. 101(3), 515-520 (1998).
72. Gutzwiller JP, Drewe J, Goke B et al.: Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus Type 2. Am. J. Physiol. 276(5pt.2), R1541-R1544 (1999).
73. Russel-Jones DS, Shaw J, Brandle M et al.: The once-daily human glucagon-like peptide-1 analog liraglutide reduces bodyweight in subjects with Type 2 diabetes, irrespective of body mass index at baseline. Diabetes 57(S1), A593-A594 (2008).
74. van Raalte DH, van Genugten RE, Linssen MM, Ouwens DM, Diamant M: Glucagon-like peptide-1 receptor agonist treatment prevents glucocorticoid- induced glucose intolerance and islet-cell dysfunction in humans. Diabetes Care 34(2), 412-417 (2011).
75. Sokos GG, Nikolaidis LA, Mankad S et al.: Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J. Cardiac Fail. 12(9), 694-699 (2006).
76. Liu Q, Anderson C, Broyde A et al.: Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure. Cardiovasc. Diabetol. 16(9), 76 (2010).
77. Field BC, Wren AM, Peters V et al.: PYY3-36 and oxyntomodulin can be additive in their effect on food intake in overweight and obese humans. Diabetes 59(7), 1635-1639 (2010).
78. International Diabetes Federation Atlas: Diabetes and Impaired Glucose Tolerance: Global Burden: Prevalence and Projections, 2010 and 2030 (2010) www.diabetesatlas.org/content/diabetes-andimpaired-glucose-tolerance Interesting information and projections for diabetes mellitus prevalence and overall burden.
79. World Health Organization: Fact Sheet No 312, Diabetes (2009) www.who.int/mediacentre/factsheets/fs312/en/index.html
80. US FDA: label approved on 11/12/2010 for BYETTA, NDA no. 021773 (2010) www.accessdata.fda.gov/drugsatfda-docs/label/2010/021773s028lbl.pdf
81. US FDA: label approved on 01/25/2010 for VICTOZA, NDA no. 022341 (2010) www.accessdata.fda.gov/drugsatfda-docs/label/2010/022341lbl.pdf
82. US FDA: label approved on 07/31/2009 for ONGLYZA, NDA no. 022350 (2009) www.accessdata.fda.gov/drugsatfda-docs/label/2009/022350lbl.pdf
83. US FDA: label approved on 09/24/2010 for JANUVIA, NDA no. 021995 (2010) www.accessdata.fda.gov/drugsatfda-docs/label/2010/021995s015s018lbl.pdf
84. Jensen K, Hirschler B: Novo gets FDA letter on once-weekly liraglutide. Reuters, Copenhagen, Denmark (2008) www.reuters.com/article/2008/12/11/ novonordisk-fda-idUSLB74617320081211
85. Novartis delivers sustained strong performance in first nine months of 2008 underpinned by accelerating growth in pharmaceuticals. Novartis, NY, USA (2008) www.novartis.com/newsroom/media-releases/en/2008/1260877.shtml
86. Obesity and overweight fact sheet No 311. World Health Organization, Int. (2006) www.who.int/mediacentre/factsheets/fs311/en/index.html